Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.
2.

Multicenter Validation of the CamGFR Model for Estimated Glomerular Filtration Rate.

Williams EH, Connell CM, Weaver JMJ, Beh I, Potts H, Whitley CT, Bird N, Al-Sayed T, Monaghan PJ, Fehr M, Cathomas R, Bertelli G, Quinton A, Lewis P, Shamash J, Wilson P, Dooley M, Poole S, Mark PB, Bookman MA, Earl H, Jodrell D, Tavaré S, Lynch AG, Janowitz T.

JNCI Cancer Spectr. 2019 Sep 19;3(4):pkz068. doi: 10.1093/jncics/pkz068. eCollection 2019 Dec.

3.

Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors.

Sale MJ, Minihane E, Monks NR, Gilley R, Richards FM, Schifferli KP, Andersen CL, Davies EJ, Vicente MA, Ozono E, Markovets A, Dry JR, Drew L, Flemington V, Proia T, Jodrell DI, Smith PD, Cook SJ.

Nat Commun. 2019 Nov 14;10(1):5167. doi: 10.1038/s41467-019-12409-w.

4.

SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer.

Ramu I, Buchholz SM, Patzak MS, Goetze RG, Singh SK, Richards FM, Jodrell DI, Sipos B, Ströbel P, Ellenrieder V, Hessmann E, Neesse A.

EBioMedicine. 2019 Oct;48:161-168. doi: 10.1016/j.ebiom.2019.09.024. Epub 2019 Oct 6.

5.

Quantifying Drug-Induced Bone Marrow Toxicity Using a Novel Haematopoiesis Systems Pharmacology Model.

Fornari C, Oplustil O'Connor L, Pin C, Smith A, Yates JWT, Cheung SYA, Jodrell DI, Mettetal JT, Collins TA.

CPT Pharmacometrics Syst Pharmacol. 2019 Nov;8(11):858-868. doi: 10.1002/psp4.12459. Epub 2019 Oct 20.

6.

Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer.

Ponz-Sarvise M, Corbo V, Tiriac H, Engle DD, Frese KK, Oni TE, Hwang CI, Öhlund D, Chio IIC, Baker LA, Filippini D, Wright K, Bapiro TE, Huang P, Smith P, Yu KH, Jodrell DI, Park Y, Tuveson DA.

Clin Cancer Res. 2019 Nov 15;25(22):6742-6755. doi: 10.1158/1078-0432.CCR-19-1398. Epub 2019 Sep 6.

PMID:
31492749
7.

Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses.

Spencer S, Köstel Bal S, Egner W, Lango Allen H, Raza SI, Ma CA, Gürel M, Zhang Y, Sun G, Sabroe RA, Greene D, Rae W, Shahin T, Kania K, Ardy RC, Thian M, Staples E, Pecchia-Bekkum A, Worrall WPM, Stephens J, Brown M, Tuna S, York M, Shackley F, Kerrin D, Sargur R, Condliffe A, Tipu HN, Kuehn HS, Rosenzweig SD, Turro E, Tavaré S, Thrasher AJ, Jodrell DI, Smith KGC, Boztug K, Milner JD, Thaventhiran JED.

J Exp Med. 2019 Sep 2;216(9):1986-1998. doi: 10.1084/jem.20190344. Epub 2019 Jun 24.

8.

Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites.

Patzak MS, Kari V, Patil S, Hamdan FH, Goetze RG, Brunner M, Gaedcke J, Kitz J, Jodrell DI, Richards FM, Pilarsky C, Gruetzmann R, Rümmele P, Knösel T, Hessmann E, Ellenrieder V, Johnsen SA, Neesse A.

EBioMedicine. 2019 Feb;40:394-405. doi: 10.1016/j.ebiom.2019.01.037. Epub 2019 Jan 30.

9.

The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression.

Wallez Y, Dunlop CR, Johnson TI, Koh SB, Fornari C, Yates JWT, Bernaldo de Quirós Fernández S, Lau A, Richards FM, Jodrell DI.

Mol Cancer Ther. 2018 Aug;17(8):1670-1682. doi: 10.1158/1535-7163.MCT-18-0010. Epub 2018 Jun 11.

10.

Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.

Koh SB, Wallez Y, Dunlop CR, Bernaldo de Quirós Fernández S, Bapiro TE, Richards FM, Jodrell DI.

Cancer Res. 2018 Jun 1;78(11):3054-3066. doi: 10.1158/0008-5472.CAN-17-3932. Epub 2018 May 7.

11.

CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype.

Candido JB, Morton JP, Bailey P, Campbell AD, Karim SA, Jamieson T, Lapienyte L, Gopinathan A, Clark W, McGhee EJ, Wang J, Escorcio-Correia M, Zollinger R, Roshani R, Drew L, Rishi L, Arkell R, Evans TRJ, Nixon C, Jodrell DI, Wilkinson RW, Biankin AV, Barry ST, Balkwill FR, Sansom OJ.

Cell Rep. 2018 May 1;23(5):1448-1460. doi: 10.1016/j.celrep.2018.03.131.

12.

Understanding Hematological Toxicities Using Mathematical Modeling.

Fornari C, O'Connor LO, Yates JWT, Cheung SYA, Jodrell DI, Mettetal JT, Collins TA.

Clin Pharmacol Ther. 2018 Oct;104(4):644-654. doi: 10.1002/cpt.1080. Epub 2018 May 1. Review.

PMID:
29604045
13.

A type III complement factor D deficiency: Structural insights for inhibition of the alternative pathway.

Sng CCT, O'Byrne S, Prigozhin DM, Bauer MR, Harvey JC, Ruhle M, Challis BG, Lear S, Roberts LD, Workman S, Janowitz T, Magiera L, Doffinger R, Buckland MS, Jodrell DJ, Semple RK, Wilson TJ, Modis Y, Thaventhiran JED.

J Allergy Clin Immunol. 2018 Jul;142(1):311-314.e6. doi: 10.1016/j.jaci.2018.01.048. Epub 2018 Mar 6. No abstract available.

14.

A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma.

Cook N, Basu B, Smith DM, Gopinathan A, Evans J, Steward WP, Palmer D, Propper D, Venugopal B, Hategan M, Anthoney DA, Hampson LV, Nebozhyn M, Tuveson D, Farmer-Hall H, Turner H, McLeod R, Halford S, Jodrell D.

Br J Cancer. 2018 Mar 20;118(6):793-801. doi: 10.1038/bjc.2017.495. Epub 2018 Feb 13.

15.

Cancer Immunotherapy Trials Underutilize Immune Response Monitoring.

Connell CM, Raby SEM, Beh I, Flint TR, Williams EH, Fearon DT, Jodrell DI, Janowitz T.

Oncologist. 2018 Jan;23(1):116-117. doi: 10.1634/theoncologist.2017-0226. Epub 2017 Oct 11.

16.

New Model for Estimating Glomerular Filtration Rate in Patients With Cancer.

Janowitz T, Williams EH, Marshall A, Ainsworth N, Thomas PB, Sammut SJ, Shepherd S, White J, Mark PB, Lynch AG, Jodrell DI, Tavaré S, Earl H.

J Clin Oncol. 2017 Aug 20;35(24):2798-2805. doi: 10.1200/JCO.2017.72.7578. Epub 2017 Jul 7.

17.

Modelling of the cancer cell cycle as a tool for rational drug development: A systems pharmacology approach to cyclotherapy.

Jackson RC, Di Veroli GY, Koh SB, Goldlust I, Richards FM, Jodrell DI.

PLoS Comput Biol. 2017 May 3;13(5):e1005529. doi: 10.1371/journal.pcbi.1005529. eCollection 2017 May.

18.

Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes.

Connell CM, Raby S, Beh I, Flint TR, Williams EH, Fearon DT, Jodrell DI, Janowitz T.

Ann Oncol. 2017 Jul 1;28(7):1678-1679. doi: 10.1093/annonc/mdx181. No abstract available.

19.

Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.

Hessmann E, Patzak MS, Klein L, Chen N, Kari V, Ramu I, Bapiro TE, Frese KK, Gopinathan A, Richards FM, Jodrell DI, Verbeke C, Li X, Heuchel R, Löhr JM, Johnsen SA, Gress TM, Ellenrieder V, Neesse A.

Gut. 2018 Mar;67(3):497-507. doi: 10.1136/gutjnl-2016-311954. Epub 2017 Jan 10.

20.

A quantitative FastFUCCI assay defines cell cycle dynamics at a single-cell level.

Koh SB, Mascalchi P, Rodriguez E, Lin Y, Jodrell DI, Richards FM, Lyons SK.

J Cell Sci. 2017 Jan 15;130(2):512-520. doi: 10.1242/jcs.195164. Epub 2016 Nov 25.

21.

Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity.

Flint TR, Janowitz T, Connell CM, Roberts EW, Denton AE, Coll AP, Jodrell DI, Fearon DT.

Cell Metab. 2016 Nov 8;24(5):672-684. doi: 10.1016/j.cmet.2016.10.010.

22.

mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.

Driscoll DR, Karim SA, Sano M, Gay DM, Jacob W, Yu J, Mizukami Y, Gopinathan A, Jodrell DI, Evans TR, Bardeesy N, Hall MN, Quattrochi BJ, Klimstra DS, Barry ST, Sansom OJ, Lewis BC, Morton JP.

Cancer Res. 2016 Dec 1;76(23):6911-6923. Epub 2016 Oct 6.

23.
24.

Combenefit: an interactive platform for the analysis and visualization of drug combinations.

Di Veroli GY, Fornari C, Wang D, Mollard S, Bramhall JL, Richards FM, Jodrell DI.

Bioinformatics. 2016 Sep 15;32(18):2866-8. doi: 10.1093/bioinformatics/btw230. Epub 2016 Apr 25.

25.

Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.

McCann KJ, Mander A, Cazaly A, Chudley L, Stasakova J, Thirdborough S, King A, Lloyd-Evans P, Buxton E, Edwards C, Halford S, Bateman A, O'Callaghan A, Clive S, Anthoney A, Jodrell DI, Weinschenk T, Simon P, Sahin U, Thomas GJ, Stevenson FK, Ottensmeier CH.

Clin Cancer Res. 2016 Oct 1;22(19):4827-4836. doi: 10.1158/1078-0432.CCR-15-2507. Epub 2016 Apr 18.

26.

Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.

Wörmann SM, Song L, Ai J, Diakopoulos KN, Kurkowski MU, Görgülü K, Ruess D, Campbell A, Doglioni C, Jodrell D, Neesse A, Demir IE, Karpathaki AP, Barenboim M, Hagemann T, Rose-John S, Sansom O, Schmid RM, Protti MP, Lesina M, Algül H.

Gastroenterology. 2016 Jul;151(1):180-193.e12. doi: 10.1053/j.gastro.2016.03.010. Epub 2016 Mar 19.

PMID:
27003603
27.

GEMMs as preclinical models for testing pancreatic cancer therapies.

Gopinathan A, Morton JP, Jodrell DI, Sansom OJ.

Dis Model Mech. 2015 Oct 1;8(10):1185-200. doi: 10.1242/dmm.021055. Review.

28.

An automated fitting procedure and software for dose-response curves with multiphasic features.

Di Veroli GY, Fornari C, Goldlust I, Mills G, Koh SB, Bramhall JL, Richards FM, Jodrell DI.

Sci Rep. 2015 Oct 1;5:14701. doi: 10.1038/srep14701.

29.

CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus.

Koh SB, Courtin A, Boyce RJ, Boyle RG, Richards FM, Jodrell DI.

Cancer Res. 2015 Sep 1;75(17):3583-95. doi: 10.1158/0008-5472.CAN-14-3347. Epub 2015 Jul 3.

30.

The use of error-category mapping in pharmacokinetic model analysis of dynamic contrast-enhanced MRI data.

Gill AB, Anandappa G, Patterson AJ, Priest AN, Graves MJ, Janowitz T, Jodrell DI, Eisen T, Lomas DJ.

Magn Reson Imaging. 2015 Feb;33(2):246-51. doi: 10.1016/j.mri.2014.10.010. Epub 2014 Nov 7.

31.

Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.

Spicer J, Baird R, Suder A, Cresti N, Corbacho JG, Hogarth L, Frenkel E, Matsumoto S, Kawabata I, Donaldson K, Posner J, Sarker D, Jodrell D, Plummer R.

Eur J Cancer. 2015 Jan;51(2):137-45. doi: 10.1016/j.ejca.2014.11.003. Epub 2014 Nov 27.

PMID:
25434923
32.

The EGFR demonstrates linear signal transmission.

Oyarzún DA, Bramhall JL, López-Caamal F, Richards FM, Jodrell DI, Krippendorff BF.

Integr Biol (Camb). 2014 Aug;6(8):736-42. doi: 10.1039/c4ib00062e.

PMID:
24934872
33.

Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo.

Bapiro TE, Frese KK, Courtin A, Bramhall JL, Madhu B, Cook N, Neesse A, Griffiths JR, Tuveson DA, Jodrell DI, Richards FM.

Br J Cancer. 2014 Jul 15;111(2):318-25. doi: 10.1038/bjc.2014.288. Epub 2014 May 29.

34.

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.

Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, Tuveson DA, Fearon DT.

Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7. doi: 10.1073/pnas.1320318110. Epub 2013 Nov 25.

35.

Design, synthesis, and biological evaluation of an allosteric inhibitor of HSET that targets cancer cells with supernumerary centrosomes.

Watts CA, Richards FM, Bender A, Bond PJ, Korb O, Kern O, Riddick M, Owen P, Myers RM, Raff J, Gergely F, Jodrell DI, Ley SV.

Chem Biol. 2013 Nov 21;20(11):1399-410. doi: 10.1016/j.chembiol.2013.09.012. Epub 2013 Oct 24.

36.

SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.

Neesse A, Frese KK, Chan DS, Bapiro TE, Howat WJ, Richards FM, Ellenrieder V, Jodrell DI, Tuveson DA.

Gut. 2014 Jun;63(6):974-83. doi: 10.1136/gutjnl-2013-305559. Epub 2013 Sep 25.

37.

Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.

Courtin A, Richards FM, Bapiro TE, Bramhall JL, Neesse A, Cook N, Krippendorff BF, Tuveson DA, Jodrell DI.

PLoS One. 2013 Jun 28;8(6):e67330. doi: 10.1371/journal.pone.0067330. Print 2013.

38.

CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.

Neesse A, Frese KK, Bapiro TE, Nakagawa T, Sternlicht MD, Seeley TW, Pilarsky C, Jodrell DI, Spong SM, Tuveson DA.

Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12325-30. doi: 10.1073/pnas.1300415110. Epub 2013 Jul 8.

39.

Cross-sectional survey of daily junk food consumption, irregular eating, mental and physical health and parenting style of British secondary school children.

Zahra J, Ford T, Jodrell D.

Child Care Health Dev. 2014 Jul;40(4):481-91. doi: 10.1111/cch.12068. Epub 2013 Apr 18.

PMID:
23594136
40.

Adaptive designs for dual-agent phase I dose-escalation studies.

Harrington JA, Wheeler GM, Sweeting MJ, Mander AP, Jodrell DI.

Nat Rev Clin Oncol. 2013 May;10(5):277-88. doi: 10.1038/nrclinonc.2013.35. Epub 2013 Mar 19. Review.

PMID:
23507740
41.

γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000).

Wu J, Clingen PH, Spanswick VJ, Mellinas-Gomez M, Meyer T, Puzanov I, Jodrell D, Hochhauser D, Hartley JA.

Clin Cancer Res. 2013 Feb 1;19(3):721-30. doi: 10.1158/1078-0432.CCR-12-2529. Epub 2012 Dec 18.

42.

Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD.

Ubhi BK, Cheng KK, Dong J, Janowitz T, Jodrell D, Tal-Singer R, MacNee W, Lomas DA, Riley JH, Griffin JL, Connor SC.

Mol Biosyst. 2012 Oct 30;8(12):3125-33. doi: 10.1039/c2mb25194a.

PMID:
23051772
43.

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells.

Lin Y, Richards FM, Krippendorff BF, Bramhall JL, Harrington JA, Bapiro TE, Robertson A, Zheleva D, Jodrell DI.

Br J Cancer. 2012 Nov 6;107(10):1692-701. doi: 10.1038/bjc.2012.450. Epub 2012 Oct 4.

44.

Progress in pancreatic cancer: moving beyond gemcitabine?

Basu B, Jodrell D.

Expert Rev Anticancer Ther. 2012 Aug;12(8):997-1000. doi: 10.1586/era.12.78. No abstract available.

PMID:
23030218
45.

Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo.

Richards FM, Tape CJ, Jodrell DI, Murphy G.

PLoS One. 2012;7(7):e40597. doi: 10.1371/journal.pone.0040597. Epub 2012 Jul 11.

46.

nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.

Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, Tuveson DA.

Cancer Discov. 2012 Mar;2(3):260-269. doi: 10.1158/2159-8290.CD-11-0242. Epub 2012 Feb 28.

47.

A novel Phase I/IIa design for early phase oncology studies and its application in the evaluation of MK-0752 in pancreatic cancer.

Whitehead J, Thygesen H, Jaki T, Davies S, Halford S, Turner H, Cook N, Jodrell D.

Stat Med. 2012 Aug 15;31(18):1931-43. doi: 10.1002/sim.5331. Epub 2012 Apr 11.

PMID:
22495759
48.

Predictive in vivo animal models and translation to clinical trials.

Cook N, Jodrell DI, Tuveson DA.

Drug Discov Today. 2012 Mar;17(5-6):253-60. Review.

PMID:
22493784
49.

Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials.

Brais RJ, Davies SE, O'Donovan M, Simpson BW, Cook N, Darbonne WC, Chilcott S, Lolkema MP, Neesse A, Lockley M, Corrie PG, Jodrell DI, Praseedom RK, Huguet EL, Jah A, Jamieson NV, de Sauvage FJ, Tuveson DA, Carroll NR.

Pancreatology. 2012 Jan-Feb;12(1):8-15. doi: 10.1016/j.pan.2011.12.009. Epub 2011 Dec 31.

PMID:
22487467
50.

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.

Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kultti A, Thompson CB, Maneval DC, Jodrell DI, Frost GI, Shepard HM, Skepper JN, Tuveson DA.

Gut. 2013 Jan;62(1):112-20. doi: 10.1136/gutjnl-2012-302529. Epub 2012 Mar 30.

Supplemental Content

Loading ...
Support Center